Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
This includes ASCO’s Journal of Clinical Oncology and its scientific meetings, including the ASCO Annual Meeting, a five-day meeting held each May/June. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting. Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
A new, large study shows that intensity modulated radiation therapy (IMRT) is better than conventional conformal radiation therapy (CRT) at reducing side effects and prostate cancer recurrences (cancer that comes back after treatment) and it is less expensive than CRT and proton therapy. Both IMRT and CRT are types of radiation therapy that are designed to aim beams of radiation directly at a tumor. IMRT is better than CRT at varying the strength of the radiation so the tumor gets more radiation and the healthy tissue gets less. Proton therapy is a type of radiation therapy that uses protons instead of x-rays to treat cancer.
A new clinical trial showed that the drug called radium-223 chloride (Ra-223), designed to treat bone metastases (cancer that has spread to the bone), helps men with metastatic castration-resistant prostate cancer live longer and slows the development of bone problems from the cancer. Castration-resistant prostate cancer is when the cancer continues to grow and spread without needing the male sex hormone testosterone.
A new drug was shown to help men with metastatic prostate cancer live longer in a recent clinical trial. Metastatic prostate cancer is cancer that has spread outside the prostate and is often difficult to treat. The drug called MDV3100 was designed to prevent male sex hormones called androgens, such as testosterone, from helping the cancer grow and spread.
A new study showed that men with early-stage prostate cancer who exercise vigorously at least three hours a week have genes that are expressed differently in the prostate than those who do not exercise as intensely. Genes are small individual collections of information within each cell of the human body. How these genes affect the body is called gene expression.
The researchers found that a little more than 7% of men who received external-beam radiation therapy experienced side effects, such as narrowing of the urethra and bleeding in the bladder, compared with a little less than 7% of men who received a prostatectomy and about 3% of men who had brachytherapy. In addition, men who had external-beam radiation therapy were much more likely to experience gastrointestinal side effects, such as bleeding from the rectum. The researchers also found that external-beam radiation therapy was more than twice as expensive as brachytherapy or prostatectomy.